
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
An initial antiretroviral regimen containing Norvir-boosted Invirase has a very low rate of treatment failure and a low risk of developing viral mutations conveying resistance to other protease inhibitors, according to research presented at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Of 258 Thai patients who began treatment with Norvir-boosted Invirase, only 4% experienced virologic failure after 12 weeks of treatment as measured by two viral load measurements over 500 copies. None of those patients developed any major protease inhibtor resistance mutations, which allowed them to be effectively switched to other protease medications. 'These results support the use of [Norvir-boosted Invirase] in first-line therapy,' the researchers conclude. The National Institutes of Health recommends the following preferred antiretroviral regimens for treatment-naive HIVers: Sustiva plus Epivir or Emtriva plus Retrovir or Viread for a nonnucleoside reverse transcriptase inhibitor-based regimen; Kaletra plus Epivir or Emtriva plus Retrovir for a protease inhibitor-based therapy.
DON'T MISS THE OUT100 SPECIAL 3 DAY MARATHON STARTING NOVEMBER 24TH!
Journey through the year’s influential Out100 – the most iconic and long-standing celebration of LGBTQ+ icons and allies – in a 1-hour television special spotlighting the LGBTQ+ people shaping the world today.
WATCH & LIVESTREAM ON ADVOCATECHANNEL.COM
AND ON THE ADVOCATE CHANNEL APP
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.